Immune globulin - Baxalta

Drug Profile

Immune globulin - Baxalta

Alternative Names: 10% HyQ; 20% SubQ; Cuvitru; Gammagard Liquid; Gammagard S/D; Human Immune Globulin for Subcutaneous Administration; HyQ; HyQvia; Ig20Gly; IGI 10% with rHuPH20; IGIV - Baxalta; IGSC - Baxalta; immune globulin intravenous; IVIG 10%; Kiovig; SCIG 20%; SHP-671

Latest Information Update: 28 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baxter International
  • Developer Baxter International; Halozyme Therapeutics; Shire
  • Class Antidementias; Antivirals; Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral nervous system diseases; Chronic inflammatory demyelinating polyradiculoneuropathy
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allotransplant rejection; Chronic lymphocytic leukaemia; Guillain-Barre syndrome; HIV infections; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders; Peripheral nervous system diseases
  • Phase III Chronic inflammatory demyelinating polyradiculoneuropathy
  • Phase II Ataxia
  • Suspended Alzheimer's disease

Most Recent Events

  • 28 May 2018 No recent reports of development identified for phase-I development in Ataxia(In the elderly, In adults) in USA (IV)
  • 02 Mar 2018 Updated adverse events data from the phase II/III North American trial in Immunodeficiency disorders presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
  • 25 Sep 2017 Baxalta initiates enrolment in a phase III trial for Immunodeficiency disorders (In children, In adolescents) (SC, Infusion) (NCT03277313)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top